Overseas equities are outperforming domestic shares for the first time in about 15 years, and some financial pros say it’s ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

Shares in TripAdvisor (TRIP) were in the red in after hours trading after surging by 16% in Thursday's session as it was ...